NDA 208054 · Blue Earth
Axumin
Fluciclovine F-18 · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 21, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
May 27, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
48
7 Phase 3, 14 recruiting
FAERS reports
102
5 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 5, 2025.
Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment ( 1 ).
Mechanism: Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells. Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells compared with surrounding normal tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewSummary Review
1 products under this application
- AXUMIN · FLUCICLOVINE F-18 9-221mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluciclovine F-18" as an intervention, any sponsor and status, largest first.
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04423211 · 804 participants (planned) · Start Oct 8, 2020 · Primary completion Dec 31, 2032
Drug: Apalutamide; Degarelix and 4 more · For: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma and 1 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Phoenix, Arizona · 341 sites in all
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPivotal-lookingActive, not recruiting
VA Office of Research and DevelopmentFederal agency
NCT04787744 · 378 participants · Start Jul 1, 2021 · Primary completion Oct 2, 2026
Drug: Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide and 6 more · For: Prostate Cancer; Oligometastasis; Oligorecurrence and 3 more
Sites: Long Beach, California; West Los Angeles, California; Washington D.C., District of Columbia · 20 sites in all
- 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer TreatmentPivotal-lookingCompleted
Blue Earth DiagnosticsIndustry
NCT02680041 · 221 participants · Start Jun 1, 2016 · Primary completion Nov 1, 2017
Drug: 18F-fluciclovine PET CT · For: Prostate Cancer
Sites: Duarte, California; Los Angeles, California; San Diego, California · 17 sites in all
- Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05053152 · 194 participants (planned) · Start Apr 20, 2022 · Primary completion Feb 1, 2029
Drug: Placebo Administration; Relugolix · For: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Ductal Adenocarcinoma and 2 more
Sites: Phoenix, Arizona; Berkeley, California; Beverly Hills, California · 245 sites in all
- FACBC Outcomes for Post ProstatectomyPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT01666808 · 165 participants · Start Sep 2012 · Primary completion Apr 18, 2022
Drug: FACBC · For: Prostate Cancer
Sites: Atlanta, Georgia
- Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain MetastasesPivotal-lookingCompleted
Blue Earth DiagnosticsIndustry
NCT04410133 · 151 participants · Start Oct 26, 2020 · Primary completion Jun 5, 2023
Drug: 18F fluciclovine · For: Brain Metastases
Sites: Birmingham, Alabama; Phoenix, Arizona; San Francisco, California · 19 sites in all
Blue Earth DiagnosticsIndustry
NCT07569926 · 142 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 31, 2027
Drug: fluciclovine (18F) · For: Prostate Cancer
Sites: San Diego, California; Atlanta, Georgia; Boston, Massachusetts · 6 sites in all
- Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesPivotal-lookingActive, not recruiting
Emory UniversityAcademic, hospital or other
NCT03762759 · 140 participants · Start May 10, 2019 · Primary completion May 19, 2025
Drug: Fluciclovine F18 · For: Prostate Adenocarcinoma
Sites: Atlanta, Georgia · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- positron emission tomogram abnormal22
- no adverse event18
- therapeutic response unexpected18
- scan abnormal11
- off label use8
- false negative investigation result7
- drug ineffective6
- injection site extravasation5
- false positive investigation result4
- therapeutic product effect decreased4
- diarrhoea3
- extravasation2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 14 |
| 2019 | 14 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 30 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 26 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [18F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer.
Alemozaffar M, Akintayo AA, Abiodun-Ojo OA, et al. · J Urol 2020 · Clinical Trial, Research Support, N.I.H., Extramural
- Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H, Jinnouchi S, Kaji Y, et al. · Jpn J Clin Oncol 2019 · Clinical Trial, Phase II, Multicenter Study
- 18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review.
Seierstad T, Hole KH, Tulipan AJ, et al. · PET Clin 2021 · Systematic Review
Sponsor: Blue Earth
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.